Immunotherapies for
emergency situations

Treatments for emerging infectious diseases and biodefense solutions.

Rectangle 2

Technology

Fab’entech is specialised in the development of polyclonal antibody treatments against emerging infectious diseases, and in the development of bio defence solutions.

This technology, initially developed by Sanofi Pasteur, has been enhanced by the Fab’entech R&D teams for more than a decade.

Polyclonal antibodies recognise then neutralise the virus or toxin in a few minutes, stop the worsening of the disease, and therefore protect the patient’s life.

Traitements

Bio defence

Fab’entech benefits from the confidence of the DGA (General Directorate of Armaments)for the production of biodefense solutions

FIND OUT MORE

Emerging infectious diseases

Fab’entech’s COVID-19 programme is one of 20 priority projects selected by the government to fight COVID-19

FIND OUT MORE

Drug intoxications

The technology used makes it possible to design treatments that are adapted to the management of drug intoxications

FIND OUT MORE

Infectious diseases

Fab’entech develops treatments intended for patients that are already infected and who are at risk of developing serious forms of the disease

FIND OUT MORE

Pipeline

Treatment

Proof of Concept

Preclinical stage

clinical
stage

development completed

FabenFLU ® - H5N1
FabenCOV ® - COVID-19
ANTIDOTE #1 Bio defence
EBOLA
ANTIDOTE #2 Infectious diseases